The FDA issued a new Drug Safety Communication Tuesday that requires a warning to be placed on all gadolinium-based contrast agents (GBCAs) for MRI use. The warning should alert providers about the possibility that gadolinium could be retained in the patient’s body, including their brain, for an extended period of time after MRI.